The U.S. Food and Drug Administration (USFDA) has completed an inspection at Natco Pharma’s formulation manufacturing facility located in Kothur, Hyderabad, India. USFDA has conducted inspection from November 12 to November 20, 2026. Upon conclusion of the inspection, the company received seven observations in the Form-483. The observations are procedural in nature.
NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products.